{"id":1925,"date":"2025-11-19T12:35:12","date_gmt":"2025-11-19T20:35:12","guid":{"rendered":"https:\/\/avisitech.com\/?p=1925"},"modified":"2026-04-03T08:03:41","modified_gmt":"2026-04-03T15:03:41","slug":"avisi-technologies-announces-positive-twelve-month-clinical-data-of-visiplate-aqueous-shunt-at-aao-2025-3","status":"publish","type":"post","link":"https:\/\/avisitech.com\/zh-hans\/avisi-technologies-announces-positive-twelve-month-clinical-data-of-visiplate-aqueous-shunt-at-aao-2025-3\/","title":{"rendered":"Avisi Technologies Announces Positive Twelve-Month Clinical Data of VisiPlate\u00ae Aqueous Shunt at AAO 2025"},"content":{"rendered":"<ul>\n<li aria-setsize=\"-1\" data-leveltext=\"\u00b7\" data-font=\"Symbol\" data-listid=\"1\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:[8226],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\u00b7&quot;,&quot;469777815&quot;:&quot;hybridMultilevel&quot;}\" data-aria-posinset=\"1\" data-aria-level=\"1\"><i><span data-contrast=\"auto\">Almost half of patients medication free at 12 months.<\/span><\/i><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559685&quot;:720,&quot;335559737&quot;:0,&quot;335559738&quot;:0,&quot;335559739&quot;:0,&quot;335559991&quot;:360}\">\u00a0<\/span><\/li>\n<\/ul>\n<ul>\n<li aria-setsize=\"-1\" data-leveltext=\"\u00b7\" data-font=\"Symbol\" data-listid=\"1\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:[8226],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\u00b7&quot;,&quot;469777815&quot;:&quot;hybridMultilevel&quot;}\" data-aria-posinset=\"2\" data-aria-level=\"1\"><i><span data-contrast=\"auto\">Vast majority of patients achieved significant IOP reduction on the same or fewer medications.\u00a0<\/span><\/i><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559685&quot;:720,&quot;335559737&quot;:0,&quot;335559738&quot;:0,&quot;335559739&quot;:0,&quot;335559991&quot;:360}\">\u00a0<\/span><\/li>\n<\/ul>\n<ul>\n<li aria-setsize=\"-1\" data-leveltext=\"\u00b7\" data-font=\"Symbol\" data-listid=\"1\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:[8226],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\u00b7&quot;,&quot;469777815&quot;:&quot;hybridMultilevel&quot;}\" data-aria-posinset=\"3\" data-aria-level=\"1\"><i><span data-contrast=\"auto\">Strong 12-month safety and efficacy results: no serious adverse events.<\/span><\/i><\/li>\n<\/ul>\n<p><span data-contrast=\"auto\">Redwood City, CA \u2013 November 3, 2025 &#8211; \/<a href=\"https:\/\/eyewire.news\/news\/avisi-technologies-announces-positive-12-month-clinical-data-on-visiplate-aqueous-shunt?c4src=article:infinite-scroll\">eyewire<\/a>\/ Avisi Technologies, Inc., an ophthalmic medical device company advancing novel, sight-saving technologies, presented positive twelve-month clinical data on VisiPlate<\/span><span data-contrast=\"auto\">\u00ae<\/span><span data-contrast=\"auto\"> Aqueous Shunt from the VITA Trial during the 2025 American Academy of Ophthalmology (AAO) annual meeting. The study was presented by Dr. Jonathan Myers, Chief of Glaucoma Service at Wills Eye Hospital, Thomas Jefferson University.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:0,&quot;335559739&quot;:0}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">The VITA Trial, a prospective pilot study designed to assess the safety and efficacy of Avisi Technologies\u2019 VisiPlate<\/span><span data-contrast=\"auto\">\u00ae<\/span><span data-contrast=\"auto\"> device, was conducted at three centers by three implanting surgeons in South Africa and treated 15 patients. All patients were diagnosed with Open Angle Glaucoma (OAG) and had no prior history of filtration surgery. The surgery was a unilateral implantation via an <\/span><i><span data-contrast=\"auto\">ab externo<\/span><\/i><span data-contrast=\"auto\"> standalone procedure.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559737&quot;:0,&quot;335559738&quot;:0,&quot;335559739&quot;:0}\">\u00a0<\/span><\/p>\n<p><b><span data-contrast=\"auto\">Result Highlights<\/span><\/b><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559737&quot;:0,&quot;335559738&quot;:0,&quot;335559739&quot;:0}\">\u00a0<\/span><\/p>\n<ul>\n<li aria-setsize=\"-1\" data-leveltext=\"\u00b7\" data-font=\"Symbol\" data-listid=\"3\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:[8226],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\u00b7&quot;,&quot;469777815&quot;:&quot;hybridMultilevel&quot;}\" data-aria-posinset=\"1\" data-aria-level=\"1\"><span data-contrast=\"auto\">Mean baseline diurnal IOP was 24.1 \u00b1 6.2 mmHg; baseline glaucoma medications were 2.0 \u00b1 1.5. Baseline Visual Field mean deviation was -11.7 \u00b1 8.6 dB.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559737&quot;:0,&quot;335559738&quot;:0,&quot;335559739&quot;:0}\">\u00a0<\/span><\/li>\n<\/ul>\n<ul>\n<li aria-setsize=\"-1\" data-leveltext=\"\u00b7\" data-font=\"Symbol\" data-listid=\"3\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:[8226],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\u00b7&quot;,&quot;469777815&quot;:&quot;hybridMultilevel&quot;}\" data-aria-posinset=\"2\" data-aria-level=\"1\"><span data-contrast=\"auto\">At <\/span><span data-contrast=\"none\">12 months, mean diurnal IOP was reduced to 13.1 \u00b1 2.6 mmHg on 1.3 \u00b1 1.5 medications, a change in diurnal IOP of \u201342.6% from baseline.\u00a0<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559737&quot;:0,&quot;335559738&quot;:0,&quot;335559739&quot;:0}\">\u00a0<\/span><\/li>\n<\/ul>\n<ul>\n<li aria-setsize=\"-1\" data-leveltext=\"\u00b7\" data-font=\"Symbol\" data-listid=\"3\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:[8226],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\u00b7&quot;,&quot;469777815&quot;:&quot;hybridMultilevel&quot;}\" data-aria-posinset=\"3\" data-aria-level=\"1\"><span data-contrast=\"none\">46.7% of subjects were on no glaucoma medication at 12 months.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559737&quot;:0,&quot;335559738&quot;:0,&quot;335559739&quot;:0}\">\u00a0<\/span><\/li>\n<\/ul>\n<ul>\n<li aria-setsize=\"-1\" data-leveltext=\"\u00b7\" data-font=\"Symbol\" data-listid=\"3\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:[8226],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\u00b7&quot;,&quot;469777815&quot;:&quot;hybridMultilevel&quot;}\" data-aria-posinset=\"4\" data-aria-level=\"1\"><span data-contrast=\"none\">No serious adverse events were reported and no patients had persistent vision loss.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559737&quot;:0,&quot;335559738&quot;:0,&quot;335559739&quot;:0}\">\u00a0<\/span><\/li>\n<\/ul>\n<p><span data-contrast=\"auto\">Dr. Jonathan Myers also reviewed individual patient cases. The review included slit lamp and Optical Coherence Tomography (OCT) images highlighting the placement of VisiPlate<\/span><span data-contrast=\"auto\">\u00ae<\/span><span data-contrast=\"auto\"> in the eye, not contacting anterior chamber structures like the iris and cornea. Emphasis was placed on the resulting low-lying and diffuse blebs, and the minimal postoperative burden.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:0,&quot;335559739&quot;:0}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">The presentation concluded with a discussion about the potential benefits of VisiPlate<\/span><b><span data-contrast=\"auto\">\u00ae<\/span><\/b><span data-contrast=\"auto\">. According to Dr. Myers, the tubeless nature of VisiPlate<\/span><span data-contrast=\"auto\">\u00ae<\/span><span data-contrast=\"auto\"> demonstrates promising effectiveness and safety in lowering IOP in OAG patients and has the potential to be a standardized filtration surgery with less postoperative management.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559737&quot;:0,&quot;335559738&quot;:0,&quot;335559739&quot;:0}\">\u00a0<\/span><\/p>\n<p><b><span data-contrast=\"auto\">About VisiPlate<\/span><\/b><b><span data-contrast=\"auto\">\u00ae<\/span><\/b><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;201341983&quot;:0,&quot;335559738&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:257}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Avisi Technologies\u2019 <\/span><a href=\"https:\/\/avisitech.com\/zh-hans\/visiplate\/\"><b><span data-contrast=\"none\">VisiPlate<\/span><\/b><b><span data-contrast=\"none\">\u00ae<\/span><\/b><\/a> <span data-contrast=\"auto\">aqueous shunt is a unique device made of a patented metamaterial that has been designed to be non-fibrotic and is many times thinner than a human hair. The device is both doctor and patient-centric, designed for ease of implantation, longevity, comfort, and aesthetics. Its multiple, redundant microchannels are engineered to provide sustained aqueous flow while minimizing the risk of blockage and re-intervention, both common challenges with currently available glaucoma surgical solutions. VisiPlate<\/span><span data-contrast=\"auto\">\u00ae<\/span><span data-contrast=\"auto\"> is being studied in the US in the <\/span><a href=\"https:\/\/avisitech.com\/clinical-trials-at-avisi-technologies\/\"><b><span data-contrast=\"none\">SAPPHIRE<\/span><\/b><\/a><span data-contrast=\"auto\"> Trial.\u00a0<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559737&quot;:0,&quot;335559738&quot;:0,&quot;335559739&quot;:0}\">\u00a0<\/span><\/p>\n<p><b><span data-contrast=\"auto\">About Glaucoma and Current Treatment:<\/span><\/b><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:0,&quot;335559739&quot;:0}\">\u00a0<\/span><\/p>\n<p><a href=\"https:\/\/avisitech.com\/zh-hans\/what-is-glaucoma-ch\/\"><b><span data-contrast=\"none\">Glaucoma<\/span><\/b><\/a><span data-contrast=\"auto\"> is the leading cause of irreversible blindness worldwide, affecting over 103 million people according to Market Scope\u2019s 2021 Glaucoma Surgical Device Market Report, and currently has no cure. In glaucoma patients, excess fluid builds up within the eye, increasing pressure on the optic nerve and leading to permanent vision loss. Glaucoma is a group of diseases, the most common of which are open-angle glaucoma and angle-closure glaucoma.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559737&quot;:0,&quot;335559738&quot;:0,&quot;335559739&quot;:0}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">OAG often has no early warning signs or symptoms. It occurs when the eye&#8217;s drainage system (trabecular meshwork) becomes clogged, preventing normal fluid outflow and leading to elevated eye pressure. Without diagnosis and treatment, OAG can cause gradual vision loss over time. Current treatments for glaucoma include medications, lasers, surgeries, and medical device solutions. However, these interventions rely on patient compliance, re-treatment, or may fail due to occlusion and scarring over time. There remains a pressing need for safe and effective long-term treatments for glaucoma that improve patient outcomes and quality of life.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559737&quot;:0,&quot;335559738&quot;:0,&quot;335559739&quot;:0}\">\u00a0<\/span><\/p>\n<p><b><span data-contrast=\"auto\">About Avisi Technologies<\/span><\/b><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:0,&quot;335559739&quot;:0}\">\u00a0<\/span><\/p>\n<p><a href=\"https:\/\/avisitech.com\/zh-hans\/\"><b><span data-contrast=\"none\">Avisi Technologies<\/span><\/b><\/a> <span data-contrast=\"auto\">is a clinical-stage medical device company committed to advancing vision care through innovative ophthalmic solutions. The company&#8217;s portfolio includes state-of-the-art treatments for glaucoma and other ocular conditions. These include its flagship VisiPlate<\/span><span data-contrast=\"auto\">\u00ae<\/span><span data-contrast=\"auto\"> aqueous shunt, V-001 sustained intraocular drug-delivery platform, and the VisiPlate-S drainage device for treating glaucoma at the time of cataract surgery. Avisi has been recognized and supported by numerous organizations, including the National Science Foundation (NSF), the Glaucoma Research Foundation, SXSW, Johnson &amp; Johnson JLABs, Medtech Innovator Accelerator, UCSF Rosenman Institute, and the University of Pennsylvania, among others. Avisi is funded by venture capital investors, angel investors, and scientific research grants. For more information, visit<\/span><span data-contrast=\"none\"> Avisi\u2019s <\/span><a href=\"https:\/\/avisitech.com\/clinical-trials-at-avisi-technologies\/\"><b><span data-contrast=\"none\">Clinical Research.<\/span><\/b><\/a><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;201341983&quot;:0,&quot;335557856&quot;:16777215,&quot;335559738&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:257}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">VisiPlate<\/span><span data-contrast=\"none\">\u00ae<\/span><span data-contrast=\"none\"> is an investigational device. The VisiPlate<\/span><span data-contrast=\"none\">\u00ae<\/span><span data-contrast=\"none\"> device is for investigational use only, and not yet available for sale.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;201341983&quot;:0,&quot;335557856&quot;:16777215,&quot;335559738&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:257}\">\u00a0<\/span><\/p>\n<p><b><i><span data-contrast=\"none\">Media Contact:<\/span><\/i><\/b><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;201341983&quot;:0,&quot;335557856&quot;:16777215,&quot;335559738&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:257}\">\u00a0<\/span><\/p>\n<p><i><span data-contrast=\"none\">Seth Harrington<\/span><\/i><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;201341983&quot;:0,&quot;335557856&quot;:16777215,&quot;335559738&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:257}\">\u00a0<\/span><\/p>\n<p><a href=\"mailto:info@avisitech.com\"><b><i><span data-contrast=\"none\">info@avisitech.com<\/span><\/i><\/b><\/a><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;201341983&quot;:0,&quot;335557856&quot;:16777215,&quot;335559738&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:257}\">\u00a0<\/span><\/p>\n<p><i><span data-contrast=\"none\">SOURCE: Avisi Technologies, Inc.<\/span><\/i><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;201341983&quot;:0,&quot;335557856&quot;:16777215,&quot;335559738&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:257}\">\u00a0<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Almost half of patients medication free at 12 months.\u00a0  [&hellip;]<\/p>\n","protected":false},"author":486,"featured_media":1666,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[28],"tags":[],"class_list":["post-1925","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-28"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Avisi Technologies Announces Positive Twelve-Month Clinical Data of VisiPlate\u00ae Aqueous Shunt at AAO 2025 - Avisi Technologies Inc.<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/avisitech.com\/zh-hans\/avisi-technologies-announces-positive-twelve-month-clinical-data-of-visiplate-aqueous-shunt-at-aao-2025-3\/\" \/>\n<meta property=\"og:locale\" content=\"zh_CN\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Avisi Technologies Announces Positive Twelve-Month Clinical Data of VisiPlate\u00ae Aqueous Shunt at AAO 2025 - Avisi Technologies Inc.\" \/>\n<meta property=\"og:description\" content=\"Almost half of patients medication free at 12 months.\u00a0 [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/avisitech.com\/zh-hans\/avisi-technologies-announces-positive-twelve-month-clinical-data-of-visiplate-aqueous-shunt-at-aao-2025-3\/\" \/>\n<meta property=\"og:site_name\" content=\"Avisi Technologies Inc.\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-19T20:35:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-03T15:03:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/avisitech.com\/wp-content\/uploads\/2025\/11\/1756845088284.png\" \/>\n\t<meta property=\"og:image:width\" content=\"600\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"ivankornienko\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u4f5c\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"ivankornienko\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u9884\u8ba1\u9605\u8bfb\u65f6\u95f4\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 \u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/avisitech.com\\\/zh-hans\\\/avisi-technologies-announces-positive-twelve-month-clinical-data-of-visiplate-aqueous-shunt-at-aao-2025-3\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/avisitech.com\\\/zh-hans\\\/avisi-technologies-announces-positive-twelve-month-clinical-data-of-visiplate-aqueous-shunt-at-aao-2025-3\\\/\"},\"author\":{\"name\":\"ivankornienko\",\"@id\":\"https:\\\/\\\/avisitech.com\\\/zh-hans\\\/#\\\/schema\\\/person\\\/8912f5bbc34efc0fee96277c64d105a5\"},\"headline\":\"Avisi Technologies Announces Positive Twelve-Month Clinical Data of VisiPlate\u00ae Aqueous Shunt at AAO 2025\",\"datePublished\":\"2025-11-19T20:35:12+00:00\",\"dateModified\":\"2026-04-03T15:03:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/avisitech.com\\\/zh-hans\\\/avisi-technologies-announces-positive-twelve-month-clinical-data-of-visiplate-aqueous-shunt-at-aao-2025-3\\\/\"},\"wordCount\":726,\"publisher\":{\"@id\":\"https:\\\/\\\/avisitech.com\\\/zh-hans\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/avisitech.com\\\/zh-hans\\\/avisi-technologies-announces-positive-twelve-month-clinical-data-of-visiplate-aqueous-shunt-at-aao-2025-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/avisitech.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1756845088284.png\",\"articleSection\":[\"\u65b0\u95fb\"],\"inLanguage\":\"zh-Hans\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/avisitech.com\\\/zh-hans\\\/avisi-technologies-announces-positive-twelve-month-clinical-data-of-visiplate-aqueous-shunt-at-aao-2025-3\\\/\",\"url\":\"https:\\\/\\\/avisitech.com\\\/zh-hans\\\/avisi-technologies-announces-positive-twelve-month-clinical-data-of-visiplate-aqueous-shunt-at-aao-2025-3\\\/\",\"name\":\"Avisi Technologies Announces Positive Twelve-Month Clinical Data of VisiPlate\u00ae Aqueous Shunt at AAO 2025 - Avisi Technologies Inc.\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/avisitech.com\\\/zh-hans\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/avisitech.com\\\/zh-hans\\\/avisi-technologies-announces-positive-twelve-month-clinical-data-of-visiplate-aqueous-shunt-at-aao-2025-3\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/avisitech.com\\\/zh-hans\\\/avisi-technologies-announces-positive-twelve-month-clinical-data-of-visiplate-aqueous-shunt-at-aao-2025-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/avisitech.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1756845088284.png\",\"datePublished\":\"2025-11-19T20:35:12+00:00\",\"dateModified\":\"2026-04-03T15:03:41+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/avisitech.com\\\/zh-hans\\\/avisi-technologies-announces-positive-twelve-month-clinical-data-of-visiplate-aqueous-shunt-at-aao-2025-3\\\/#breadcrumb\"},\"inLanguage\":\"zh-Hans\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/avisitech.com\\\/zh-hans\\\/avisi-technologies-announces-positive-twelve-month-clinical-data-of-visiplate-aqueous-shunt-at-aao-2025-3\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\\\/\\\/avisitech.com\\\/zh-hans\\\/avisi-technologies-announces-positive-twelve-month-clinical-data-of-visiplate-aqueous-shunt-at-aao-2025-3\\\/#primaryimage\",\"url\":\"https:\\\/\\\/avisitech.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1756845088284.png\",\"contentUrl\":\"https:\\\/\\\/avisitech.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1756845088284.png\",\"width\":600,\"height\":600},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/avisitech.com\\\/zh-hans\\\/avisi-technologies-announces-positive-twelve-month-clinical-data-of-visiplate-aqueous-shunt-at-aao-2025-3\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/avisitech.com\\\/zh-hans\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Avisi Technologies Announces Positive Twelve-Month Clinical Data of VisiPlate\u00ae Aqueous Shunt at AAO 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/avisitech.com\\\/zh-hans\\\/#website\",\"url\":\"https:\\\/\\\/avisitech.com\\\/zh-hans\\\/\",\"name\":\"Avisi Technologies Inc.\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/avisitech.com\\\/zh-hans\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/avisitech.com\\\/zh-hans\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"zh-Hans\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/avisitech.com\\\/zh-hans\\\/#organization\",\"name\":\"Avisi Technologies Inc.\",\"url\":\"https:\\\/\\\/avisitech.com\\\/zh-hans\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\\\/\\\/avisitech.com\\\/zh-hans\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/avisitech.com\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/Avisi-Technologies-Logo-SVG-Final-1.svg\",\"contentUrl\":\"https:\\\/\\\/avisitech.com\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/Avisi-Technologies-Logo-SVG-Final-1.svg\",\"width\":124,\"height\":43,\"caption\":\"Avisi Technologies Inc.\"},\"image\":{\"@id\":\"https:\\\/\\\/avisitech.com\\\/zh-hans\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/avisitech.com\\\/zh-hans\\\/#\\\/schema\\\/person\\\/8912f5bbc34efc0fee96277c64d105a5\",\"name\":\"ivankornienko\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/302018db4e1d52c0124450ceca39d595309c13b7907918bd1357932b410ecc81?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/302018db4e1d52c0124450ceca39d595309c13b7907918bd1357932b410ecc81?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/302018db4e1d52c0124450ceca39d595309c13b7907918bd1357932b410ecc81?s=96&d=mm&r=g\",\"caption\":\"ivankornienko\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Avisi Technologies Announces Positive Twelve-Month Clinical Data of VisiPlate\u00ae Aqueous Shunt at AAO 2025 - Avisi Technologies Inc.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/avisitech.com\/zh-hans\/avisi-technologies-announces-positive-twelve-month-clinical-data-of-visiplate-aqueous-shunt-at-aao-2025-3\/","og_locale":"zh_CN","og_type":"article","og_title":"Avisi Technologies Announces Positive Twelve-Month Clinical Data of VisiPlate\u00ae Aqueous Shunt at AAO 2025 - Avisi Technologies Inc.","og_description":"Almost half of patients medication free at 12 months.\u00a0 [&hellip;]","og_url":"https:\/\/avisitech.com\/zh-hans\/avisi-technologies-announces-positive-twelve-month-clinical-data-of-visiplate-aqueous-shunt-at-aao-2025-3\/","og_site_name":"Avisi Technologies Inc.","article_published_time":"2025-11-19T20:35:12+00:00","article_modified_time":"2026-04-03T15:03:41+00:00","og_image":[{"width":600,"height":600,"url":"https:\/\/avisitech.com\/wp-content\/uploads\/2025\/11\/1756845088284.png","type":"image\/png"}],"author":"ivankornienko","twitter_card":"summary_large_image","twitter_misc":{"\u4f5c\u8005":"ivankornienko","\u9884\u8ba1\u9605\u8bfb\u65f6\u95f4":"4 \u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/avisitech.com\/zh-hans\/avisi-technologies-announces-positive-twelve-month-clinical-data-of-visiplate-aqueous-shunt-at-aao-2025-3\/#article","isPartOf":{"@id":"https:\/\/avisitech.com\/zh-hans\/avisi-technologies-announces-positive-twelve-month-clinical-data-of-visiplate-aqueous-shunt-at-aao-2025-3\/"},"author":{"name":"ivankornienko","@id":"https:\/\/avisitech.com\/zh-hans\/#\/schema\/person\/8912f5bbc34efc0fee96277c64d105a5"},"headline":"Avisi Technologies Announces Positive Twelve-Month Clinical Data of VisiPlate\u00ae Aqueous Shunt at AAO 2025","datePublished":"2025-11-19T20:35:12+00:00","dateModified":"2026-04-03T15:03:41+00:00","mainEntityOfPage":{"@id":"https:\/\/avisitech.com\/zh-hans\/avisi-technologies-announces-positive-twelve-month-clinical-data-of-visiplate-aqueous-shunt-at-aao-2025-3\/"},"wordCount":726,"publisher":{"@id":"https:\/\/avisitech.com\/zh-hans\/#organization"},"image":{"@id":"https:\/\/avisitech.com\/zh-hans\/avisi-technologies-announces-positive-twelve-month-clinical-data-of-visiplate-aqueous-shunt-at-aao-2025-3\/#primaryimage"},"thumbnailUrl":"https:\/\/avisitech.com\/wp-content\/uploads\/2025\/11\/1756845088284.png","articleSection":["\u65b0\u95fb"],"inLanguage":"zh-Hans"},{"@type":"WebPage","@id":"https:\/\/avisitech.com\/zh-hans\/avisi-technologies-announces-positive-twelve-month-clinical-data-of-visiplate-aqueous-shunt-at-aao-2025-3\/","url":"https:\/\/avisitech.com\/zh-hans\/avisi-technologies-announces-positive-twelve-month-clinical-data-of-visiplate-aqueous-shunt-at-aao-2025-3\/","name":"Avisi Technologies Announces Positive Twelve-Month Clinical Data of VisiPlate\u00ae Aqueous Shunt at AAO 2025 - Avisi Technologies Inc.","isPartOf":{"@id":"https:\/\/avisitech.com\/zh-hans\/#website"},"primaryImageOfPage":{"@id":"https:\/\/avisitech.com\/zh-hans\/avisi-technologies-announces-positive-twelve-month-clinical-data-of-visiplate-aqueous-shunt-at-aao-2025-3\/#primaryimage"},"image":{"@id":"https:\/\/avisitech.com\/zh-hans\/avisi-technologies-announces-positive-twelve-month-clinical-data-of-visiplate-aqueous-shunt-at-aao-2025-3\/#primaryimage"},"thumbnailUrl":"https:\/\/avisitech.com\/wp-content\/uploads\/2025\/11\/1756845088284.png","datePublished":"2025-11-19T20:35:12+00:00","dateModified":"2026-04-03T15:03:41+00:00","breadcrumb":{"@id":"https:\/\/avisitech.com\/zh-hans\/avisi-technologies-announces-positive-twelve-month-clinical-data-of-visiplate-aqueous-shunt-at-aao-2025-3\/#breadcrumb"},"inLanguage":"zh-Hans","potentialAction":[{"@type":"ReadAction","target":["https:\/\/avisitech.com\/zh-hans\/avisi-technologies-announces-positive-twelve-month-clinical-data-of-visiplate-aqueous-shunt-at-aao-2025-3\/"]}]},{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/avisitech.com\/zh-hans\/avisi-technologies-announces-positive-twelve-month-clinical-data-of-visiplate-aqueous-shunt-at-aao-2025-3\/#primaryimage","url":"https:\/\/avisitech.com\/wp-content\/uploads\/2025\/11\/1756845088284.png","contentUrl":"https:\/\/avisitech.com\/wp-content\/uploads\/2025\/11\/1756845088284.png","width":600,"height":600},{"@type":"BreadcrumbList","@id":"https:\/\/avisitech.com\/zh-hans\/avisi-technologies-announces-positive-twelve-month-clinical-data-of-visiplate-aqueous-shunt-at-aao-2025-3\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/avisitech.com\/zh-hans\/"},{"@type":"ListItem","position":2,"name":"Avisi Technologies Announces Positive Twelve-Month Clinical Data of VisiPlate\u00ae Aqueous Shunt at AAO 2025"}]},{"@type":"WebSite","@id":"https:\/\/avisitech.com\/zh-hans\/#website","url":"https:\/\/avisitech.com\/zh-hans\/","name":"Avisi Technologies Inc.","description":"","publisher":{"@id":"https:\/\/avisitech.com\/zh-hans\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/avisitech.com\/zh-hans\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"zh-Hans"},{"@type":"Organization","@id":"https:\/\/avisitech.com\/zh-hans\/#organization","name":"Avisi Technologies Inc.","url":"https:\/\/avisitech.com\/zh-hans\/","logo":{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/avisitech.com\/zh-hans\/#\/schema\/logo\/image\/","url":"https:\/\/avisitech.com\/wp-content\/uploads\/2024\/01\/Avisi-Technologies-Logo-SVG-Final-1.svg","contentUrl":"https:\/\/avisitech.com\/wp-content\/uploads\/2024\/01\/Avisi-Technologies-Logo-SVG-Final-1.svg","width":124,"height":43,"caption":"Avisi Technologies Inc."},"image":{"@id":"https:\/\/avisitech.com\/zh-hans\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/avisitech.com\/zh-hans\/#\/schema\/person\/8912f5bbc34efc0fee96277c64d105a5","name":"ivankornienko","image":{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/secure.gravatar.com\/avatar\/302018db4e1d52c0124450ceca39d595309c13b7907918bd1357932b410ecc81?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/302018db4e1d52c0124450ceca39d595309c13b7907918bd1357932b410ecc81?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/302018db4e1d52c0124450ceca39d595309c13b7907918bd1357932b410ecc81?s=96&d=mm&r=g","caption":"ivankornienko"}}]}},"_links":{"self":[{"href":"https:\/\/avisitech.com\/zh-hans\/wp-json\/wp\/v2\/posts\/1925","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/avisitech.com\/zh-hans\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/avisitech.com\/zh-hans\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/avisitech.com\/zh-hans\/wp-json\/wp\/v2\/users\/486"}],"replies":[{"embeddable":true,"href":"https:\/\/avisitech.com\/zh-hans\/wp-json\/wp\/v2\/comments?post=1925"}],"version-history":[{"count":0,"href":"https:\/\/avisitech.com\/zh-hans\/wp-json\/wp\/v2\/posts\/1925\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/avisitech.com\/zh-hans\/wp-json\/wp\/v2\/media\/1666"}],"wp:attachment":[{"href":"https:\/\/avisitech.com\/zh-hans\/wp-json\/wp\/v2\/media?parent=1925"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/avisitech.com\/zh-hans\/wp-json\/wp\/v2\/categories?post=1925"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/avisitech.com\/zh-hans\/wp-json\/wp\/v2\/tags?post=1925"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}